Skip to content

Medical emergency? What to do

Merck cutting AIDS drug price in poor countries

3-RXPublished March 8, 20062 min read

Key points

  • Inc. is cutting the price charged for its brand-name version of efavirenz (sold as Sustiva in the U.S. and Stocrin in Europe) for HIV infection by 20 percent in poor countries, bringing it within "pennies" of the cost of generics, the U.S. drug maker said on Tuesday.
  • Merck has come under pressure to cut the cost of the life-saving drug following moves earlier this year by the Clinton Foundation to help producers in India and South Africa make cheap generic versions of the medicine.
  • The scheme backed by former President Bill Clinton offers efavirenz, the generic version, for $240 a year.
  • "At the end of the day, the prices we're making available are within pennies of those offered by the generic producers," said Merck spokesman Jeffrey Sturchio.

Merck & Co. Inc. is cutting the price charged for its brand-name version of efavirenz (sold as Sustiva in the U.S. and Stocrin in Europe) for HIV infection by 20 percent in poor countries, bringing it within "pennies" of the cost of generics, the U.S. drug maker said on Tuesday.

The lower price reflects new efficiencies and cost savings resulting from improved manufacturing processes at a new factory for making the drug in Australia, the company said.

Merck has come under pressure to cut the cost of the life-saving drug following moves earlier this year by the Clinton Foundation to help producers in India and South Africa make cheap generic versions of the medicine.

Merck's new price for the 600 milligram formulation is 76 U.S. cents per day, or $277.40 per patient a year, down from 95 cents, in the least developed countries of the world and those hardest hit by the HIV/AIDS pandemic.

The scheme backed by former President Bill Clinton offers efavirenz, the generic version, for $240 a year.

But this lower price is limited to large orders and does not include shipping and insurance, which Merck estimates adds around 10 percent to the final cost.

"At the end of the day, the prices we're making available are within pennies of those offered by the generic producers," said Merck spokesman Jeffrey Sturchio.

Efavirenz is often used in patients who have become resistant to first-line drugs or cannot tolerate the side effects. Campaigners have been pushing hard to bring down the cost of such second-line therapies, after a successful fight in the past five years to slash the price of cheaper initial medications.

Like other HIV/AIDS drugs, efavirenz is given in combination with other antiretrovirals to minimise the risk of the virus developing resistance to treatment.

Dr. Peter Piot, executive director of the Joint United Nations Program on HIV/AIDS (UNAIDS), said the Merck move was "very welcome" and he hoped it would be part of a continuing trend to bring down prices further.

Cutting costs is crucial if the global community is to achieve its goal of getting universal access to HIV treatment and care for all who need it by 2010.

Merck Chief Executive Richard Clark said the Whitehouse Station, N.J.-based company hoped to be able to reduce the price of the drug again as efficiencies continued to improve.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underAIDS/HIV

Keep reading

AIDS/HIV

Economic crisis could worsen HIV/AIDS epidemic: UN

Economic crisis and climate change concerns could affect the fight against the AIDS virus and lead to a "universal nightmare", the head of the United Nations' agency for HIV/AIDS said on Sunday. The global economic…

2 min read

AIDS/HIV

Possible cure for HIV patients?

On December 7th, an article was published in PLoS One that explained that researchers from UCLA AIDS Institute have found a way to use human stem cells to fight HIV-infected cells. The human stem cells can be…

1 min read

AIDS/HIV

HIV-infected Chinese children struggle with stigma

The second storey of this nondescript building in Fuyang city in China's central province of Anhui houses HIV-positive orphans, but unlike many other similar establishments, there are no signboards outside. Heavy…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.